Brokerages predict that G1 Therapeutics Inc (NASDAQ:GTHX) will announce ($0.85) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for G1 Therapeutics’ earnings. The highest EPS estimate is ($0.73) and the lowest is ($0.92). G1 Therapeutics reported earnings of ($0.59) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 44.1%. The firm is scheduled to report its next earnings results on Wednesday, November 6th.
According to Zacks, analysts expect that G1 Therapeutics will report full-year earnings of ($3.20) per share for the current fiscal year, with EPS estimates ranging from ($3.48) to ($2.96). For the next fiscal year, analysts anticipate that the firm will post earnings of ($4.09) per share, with EPS estimates ranging from ($4.57) to ($3.52). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for G1 Therapeutics.
G1 Therapeutics (NASDAQ:GTHX) last issued its earnings results on Wednesday, August 7th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by ($0.09).
A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. raised shares of G1 Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $38.00 to $45.00 in a report on Thursday, August 8th. BidaskClub raised shares of G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, June 24th. Zacks Investment Research cut shares of G1 Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 16th. ValuEngine raised shares of G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a report on Tuesday, June 18th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $61.00.
GTHX traded up $6.56 on Friday, reaching $38.01. The stock had a trading volume of 287,384 shares, compared to its average volume of 387,573. G1 Therapeutics has a 12-month low of $13.87 and a 12-month high of $69.57. The company has a 50-day moving average price of $27.30. The company has a market cap of $1.12 billion, a P/E ratio of -14.85 and a beta of 2.66.
Several hedge funds have recently added to or reduced their stakes in the company. FMR LLC increased its stake in shares of G1 Therapeutics by 0.6% during the first quarter. FMR LLC now owns 5,611,235 shares of the company’s stock worth $93,147,000 after purchasing an additional 33,481 shares in the last quarter. BlackRock Inc. increased its stake in shares of G1 Therapeutics by 27.4% during the second quarter. BlackRock Inc. now owns 2,468,415 shares of the company’s stock worth $75,681,000 after purchasing an additional 530,999 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of G1 Therapeutics by 5.4% during the second quarter. Vanguard Group Inc. now owns 1,976,615 shares of the company’s stock worth $60,603,000 after purchasing an additional 100,523 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of G1 Therapeutics by 27.8% during the second quarter. JPMorgan Chase & Co. now owns 1,429,138 shares of the company’s stock worth $44,446,000 after purchasing an additional 310,614 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of G1 Therapeutics by 4.2% during the second quarter. Northern Trust Corp now owns 302,452 shares of the company’s stock worth $9,273,000 after purchasing an additional 12,300 shares in the last quarter. 73.58% of the stock is owned by institutional investors and hedge funds.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.
Recommended Story: Buy-Side Analysts
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.